You are here

Third Positive Recommendation From Independent Safety Review Board Encourages the Continuation of Alzhemed Trial

LAVAL, Canada, Oct. 5 /PRNewswire-FirstCall/ -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued a third recommendation to continue the Company's North American Phase III clinical trial for Alzhemed(TM), an investigational product candidate for the treatment of Alzheimer's disease (AD). The recommendation by the ISRB members was based on their recent review of the safety data from 1,042 patients who have been on study medication for an average of 20 weeks.

Neurochem's ISRB for Alzhemed(TM) is made up of independent medical experts who monitor and evaluate the safety of patients taking part in the Alzhemed(TM) Phase III clinical trial in North America.

About Alzhemed
Alzhemed(TM) has entered into a multicenter, randomized, double-blind, placebo-controlled, three-armed, parallel-design Phase III clinical trial; 68 clinical centers have been enrolled in North America. A total of 1,052 patients have been randomized to receive study medication over a period of 18 months. The Company also launched its Phase III clinical trial in Europe in September 2005.

Source: Neurochem Inc. Alzhemed(TM) is an orally administered, small organic molecule that has been specifically designed to modify the course of AD through its anti-amyloid activity. As part of a "disease modifying" novel class of product candidates, Alzhemed(TM) is expected to act at two levels: by preventing and stopping the formation and the deposition of amyloid fibrils in the brain and by binding to soluble A(beta) protein to reduce the amyloid-induced toxicity on neuronal and brain inflammatory cells associated with amyloid build-up in AD.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs